JWC masterclass on skin substitutes. 2021. (accessed 21 February 2022)

Lantis JC, Snyder R, Reyzelman AM Fetal bovine acellular dermal matrix for the closure of diabetic foot ulcers: a prospective randomised controlled trial. J Wound Care. 2021; 30:S18-S27

Azhar FF, Rostamzadeh P, Khordadmehr M, Mesgari-Abbasi M. Evaluation of a novel bioactive wound dressing: an in vitro and in vivo study. J Wound Care. 2021; 30:(6)482-490

Ai-Jalodi O, Sabo M, Patel K Efficacy and safety of a porcine peritoneum-derived matrix in diabetic foot ulcer treatment: a pilot study. J Wound Care. 2021; 30:S18-S23

Tsai GL, Zilberbrand D, Liao WJ, Horl LP. Healing hard-to-heal diabetic foot ulcers: the role of dehydrated amniotic allograft with cross-linked bovine-tendon collagen and glycosaminoglycan matrix. J Wound Care. 2021; 30:S47-S53

Braizat O, Tettelbach W, Ismail A The challenges of abdominal wall defects: algorithmic integration of a placenta-derived allograft. J Wound Care. 2021; 30:S46-S51

Shim HS, Park KS, Kim SW. Preventing postoperative adhesions after hand tendon repair using acellular dermal matrix. J Wound Care. 2021; 30:(11)890-895

Chaffin AE, Dowling SG, Kosyk MS, Bosque BA. Surgical reconstruction of pilonidal sinus disease with concomitant extracellular matrix graft placement: a case series. J Wound Care. 2021; 30:S28-S34

Massand S, Lewcun JA, LaRosa CA. Clinical and cost efficacy of advanced wound care matrices in the treatment of venous leg ulcers: a systematic review. J Wound CAre. 2021; 30:(7)553-561

Armstrong DG, Tettelbach WH, Chang TJ Observed impact of skin substitutes in lower extremity diabetic ulcers: lessons from the medicare database (2015–2018). J Wound Care. 2021; 30:S5-S16

Tettelbach WH, Armstrong DG, Chang TJ Cost-effectiveness of dehydrated human amnion/chorion membrane allografts in lower extremity diabetic ulcer treatment. J Wound Care. 2022; 31:S10-S31

Atkin L, Bućko Z, Montero EC Implementing TIMERS: the race against hard-to-heal wounds. J Wound Care. 2019; 23:S1-S50

Increasing evidence for skin substitute efficacy in 2021

02 February 2022
3 min read
Volume 6 · Issue 1

The year 2021 led to increasing consensus on the role of skin substitutes in closing hard-to-heal wounds.1 The Association for the Advancement of Wound Care (AAWC), along with its members, have continued to strive to fulfil its mission to advance the care of patients with and at-risk of wounds, through contributions to this growing library of evidence.

Promising studies examined non-human grafts that provide extracellular matrix (ECM) structure and composition, while differing in their source and decellularisation processing techniques. These include:

The porcine peritoneum-derived matrix was executed as a 12-person pilot study,4 and FBADM was evaluated in a 226-person randomised controlled trial (RCT).2 FBADM was found to be a faster and more effective treatment for diabetic foot ulcers (DFUs) than standard of care (SOC) alone. Importantly, all products in the skin substitute or cellular and/or tissue-based products space demonstrated safety while others exhibited varying desirable features such as bactericidal activity, low scarring, and improved wound healing.2,3,4,5 Continuing maturation of non-human allograft options promises a broader supply of skin substitute materials with greater patient access.

Register now to continue reading

Thank you for visiting Wound Central and reading some of our peer-reviewed resources for wound care professionals. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Access to clinical or professional articles

  • New content and clinical updates each month